RxDoctor Payments Data

Neil Patel, MD

Cardiovascular Disease · Chambersburg, PANPI 1114300522

Payments from drug & device makers

$2,025in general payments, 2019–2025

Across 24 payments — averaging $84.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$443
  • E.r. Squibb & Sons, L.L.C.$356
  • Amgen$315
  • Medtronic$303
  • Abbott$208
  • Abiomed$139
  • plus $261 from 4 others

What the payments were for

  • Food & beverage$1,74286%
  • Education$28314%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,025 in reported general payments places this provider in the 50th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$117,345
Medicare patients
1,430
Services billed
2,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban167$176,229
EntrestoSacubitril/Valsartan75$65,568
JardianceEmpagliflozin59$57,876
Repatha SureclickEvolocumab18$17,489
XareltoRivaroxaban17$17,131
Praluent PenAlirocumab13$8,903
Metoprolol Succinate234$4,410
Atorvastatin Calcium86$1,208
Bumetanide38$1,135
Ezetimibe44$1,012
ClopidogrelClopidogrel Bisulfate51$851
Carvedilol88$815
Isosorbide Mononitrate ErIsosorbide Mononitrate73$756
Amiodarone Hcl39$720
Losartan Potassium52$609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$99$176,229167 claims
Johnson & JohnsonXarelto$15$17,13117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Chambersburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →